Navigation Links
ProLindac in Medical News

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

... prolindac Showing High DACH Platinum Activity; Drug Well Tol...s in the Company's clinical development plan for prolindac , a novel DACH platinum drug that has shown t...lts from its Phase 2 monotherapy clinical study of prolindac (TM) in late-stage, heavily pretreated ovarian ...

Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and other product candidates, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the v...

Access Pharmaceuticals Closes Acquisition of MacroChem Corp.

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008

... - prolindac Is Safe And Active in Recurrent Ovarian Cancer; Un... France where the level of anti-cancer activity of prolindac in a heavily-pretreated patient population compare...s in France, demonstrate the potential benefits of prolindac over current platinum therapies: one highlights th...
ProLindac in Medical Technology

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical development strategy for ProLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human cli...

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Company Announces Clinical Trial Plans for 4Q07/1Q08 DALLAS, Aug. 20 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) provided today an update on the clinical development plan of ProLindac, its novel DACH platinum polymer prodrug, and announced plans ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... high dose groups achieved disease stabilization. prolindac was well tolerated overall. DALLAS, March 5 /...ffect of the approved DACH platinum, Eloxatin, and prolindac was well tolerated overall. The maximum tolerated dose of prolindac was established as well as the recommended dose le...

Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea

...lop and commercialize Access' proprietary products prolindac and MuGard for the Republic of Korea. prolindac is Access' novel DACH platinum prodrug currently i...h a double digit royalty upon commercialization of prolindac and MuGard. In addition, in co-operation with Acce...

Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium

... prolindac Demonstrates Sustained and Significant Reductions ...Efficacy Results from an Ongoing Clinical Study of prolindac in Recurrent Ovarian Cancer." prolindac is Access' novel DACH platinum-polymer prodrug, wh...

Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...potential benefits for cancer therapy of combining prolindac with other anticancer agents. "These studies, whi...s year, provide further support to our belief that prolindac has the potential to become an important tool in t...he second poster demonstrates that combinations of prolindac with certain other anticancer compounds produces c...

Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...n San Francisco, CA. An update on Access' ongoing prolindac Phase 2 clinical study will be presented during Po...uesday, October 23, 2007 from 12:30 p.m. PDT. New prolindac preclinical data will appear in two posters presen...toxics, in human colon and ovarian cancer cells." prolindac is a novel DACH platinum prodrug which has been sh...

Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting

...titutes in France. "We are delighted to have two prolindac poster presentations at one of the most prestigiou...re platinum could be administered to patients with prolindac than oxaliplatin before the onset of toxicity. We are currently studying prolindac in a Phase 2 monotherapy trial, treating patients ...
ProLindac in Biological Technology

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

...nd that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue a...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting

... - Data demonstrates that prolindac should provide sustained tumor exposure to platinu...iopolymer" was presented on Monday, April 20. prolindac is Access' novel polymer-based DACH platinum prodr...ovides in vitro and ex-vivo data on the binding of prolindac to blood components, and suggests a mechanistic ra...

Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference

...nd can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob . The replay can be obtained at the same link for 90 days. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals to Present at the Noble Financial Equity Conference

...ommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.

...hese opportunities involve compounds that MacroChem believes show promising late-stage, pre-clinical and early clinical data. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

...he Macau Special Administrative Region and Taiwan. prolindac is Access' novel DACH platinum prodrug currently i...r obtaining the necessary regulatory approvals for prolindac and commercializing the product in the Greater Chi...an of ASK. "We are excited about the potential for prolindac in China, and we are committed to bringing excitin...

Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

....wsw.com/webcast/rrshq13/accp.ob . The replay can be obtained at the same link for up to 90 days after the live presentation. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Announces $2.7 Million New Equity

... Stock will be amended. Closing of the transaction is subject to the fulfillment of customary and usual closing conditions. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...
Other Tags
(Date:6/2/2015)... Diego, CA (PRWEB) June 02, 2015 “We ... from damaging ultraviolet (UV) sun rays”, states Marta Phillips, owner ... selection of men’s sun hats and sun accessories that work ... exposure are not immediately evident. Sometimes sun damage can take ... ears and neck are prime areas for skin cancer to ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Lynn Lester as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... honor Lynn Lester with this prestigious award,” said NAPW ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into the NAPW VIP Professional Woman of ... distinction for leadership in academics. With more than 700,000 ... the nation’s leading networking organization exclusively for professional women. ... distinction,” said NAPW President Star Jones. “She is a ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Linda Cade as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to recognize Linda with this important honor,” said NAPW ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Selma Tansey as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than 700,000 ... pleased to present Selma with this important honor," said ...
Breaking Medicine News(10 mins):Health News:It is Time to Show Father Who Knows Best, Says SunGrubbies.com, a Leading Online Sun Protection Retailer 2Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
Other Contents